A series of N-substituted lobelane analogues was synthesized and evaluated for their [3H]dihydrotetrabenazine binding affinity at the vesicular monoamine transporter and for their inhibition of vesicular [3H]dopamine uptake. Compound 19a, which contains an N-1,2(R)-dihydroxypropyl group, had been identified as a potential clinical candidate for the treatment of methamphetamine abuse.
我们合成了一系列 N-取代的洛贝兰类似物,并评估了它们在囊泡单胺转运体上的[3H]二氢四苄
肼结合亲和力及其对囊泡[3H]
多巴胺摄取的抑制作用。化合物 19a 含有一个 N-1,2(R)-二羟基丙基,已被确定为治疗甲基苯
丙胺滥用的潜在临床候选药物。